Angiogenesis Receptor Tyrosine Kinase Antibody Sampler Kit #78451
Product Information
Kit Usage Information
Protocols
- 2478: Western Blotting
- 3166: Western Blotting, Immunoprecipitation (Magnetic)
- 3169: Western Blotting, Immunoprecipitation (Magnetic), Immunohistochemistry (Paraffin), IF-F Citrate Retrieval (Rabbit), Immunofluorescence
- 4221: Western Blotting
- 7074: Western Blotting
- 7403: Western Blotting
- 9698: Western Blotting, Immunoprecipitation (Agarose), Immunohistochemistry (Paraffin), Immunofluorescence, Flow
- 9740: Western Blotting, Immunoprecipitation (Magnetic), Immunohistochemistry (Paraffin), Immunofluorescence, Flow
- 50661: Western Blotting, Immunoprecipitation (Magnetic)
- 52928: Western Blotting, Immunoprecipitation (Agarose), Immunofluorescence
Product Description
The Angiogenesis Receptor Tyrosine Kinase Antibody Sampler Kit provides an economical means of detecting the activation of VEGF receptor 2, FGF receptor 1, PDGF receptor beta, Tie2, and VEGF-A using phospho-specific and control antibodies. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.
Background
Angiogenesis is defined as the physiological process by which new blood vessels are formed from pre-existing blood vessels. It is a critical process that enables specific physiological conditions in healthy adults, including development, skeletal muscle hypertrophy, and wound healing (1,2). Angiogenesis can be aberrantly activated to generate new blood vessels during pathological conditions such as cancer, neovascular disorders, and chronic inflammation. Angiogenesis is a complicated process regulated by multiple mechanisms and pathways (3). VEGFR2 is a member of the family of receptor tyrosine kinases (RTKs) mainly located in endothelial cells and is a major player in angiogenesis. VEGF-VEGFR2 ligand-receptor activation is the key signaling pathway for angiogenesis activation (4,5). Multiple non-VEGF RTK activations can replace VEGFR to promote angiogenesis (6,7), including PDGFR (9), FGFR (8), and Tie2 (10). These RTKs are targets for an antiangiogenic based disease treatment (11,12).
- Malapelle, U. and Rossi, A. (2019) Expert Opin Emerg Drugs 24, 71-81.
- Chung, A.S. et al. (2010) Nat Rev Cancer 10, 505-14.
- Jain, R.K. (2003) Nat Med 9, 685-93.
- Leung, D.W. et al. (1989) Science 246, 1306-9.
- Jeltsch, M. et al. (2013) Cold Spring Harb Perspect Biol 5, a009183. doi: 10.1101/cshperspect.a009183.
- Zhao, Y. and Adjei, A.A. (2015) Oncologist 20, 660-73.
- Vimalraj, S. (2022) Int J Biol Macromol 221, 1428-1438.
- Lieu, C. et al. (2011) Clin Cancer Res 17, 6130-9.
- Hellberg, C. et al. (2010) Recent Results Cancer Res 180, 103-14.
- Duran, C.L. et al. (2021) Cancers (Basel) 13, 5730. doi: 10.3390/cancers13225730.
- Ramjiawan, R.R. et al. (2017) Angiogenesis 20, 185-204.
- Socinski, M.A. (2011) Cancer Treat Rev 37, 611-7.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.